A Płużańska

18.3k citations

65 papers · 11.6k indexed · 5 hit papers · h-index 28

Impact in

Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
Oncology top 0.2%
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research

Papers in

Oncology 32
- Cancer Treatment and Pharmacology 18
- Lung Cancer Research Studies 10
- Colorectal Cancer Treatments and Studies 5
- HER2/EGFR in Cancer Research 4
Pulmonary and Respiratory Medicine 29
- Lung Cancer Treatments and Mutations 13
- Lung Cancer Diagnosis and Treatment 7
- Renal cell carcinoma treatment 5

Co-authors: Nicholas D. James Ronald de Wit Mario A. Eisenberger Stéphane Oudard Ian F. Tannock Christine Théodore J Horti Mark Rosenthal
Journals: Journal of Clinical Oncology (18 papers)European Journal of Cancer (4 papers)Annals of Oncology (4 papers)Lung Cancer (4 papers)British Journal of Cancer (2 papers)
Partner nations: Poland Germany United Kingdom

In The Last Decade

A Płużańska

62 papers receiving 11.2k citations

Hit Papers

5 papers align trajectories log scale

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial 2007 · 1.7k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2007 The Lancet
2007 Journal of Clinical Oncology
2004 New England Journal of Medicine
2004 Journal of Clinical Oncology
2003 Journal of Clinical Oncology

Peers

Countries citing papers authored by A Płużańska

Since Specialization

Citations

This map shows the geographic impact of A Płużańska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Płużańska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Płużańska more than expected).

Fields of papers citing papers by A Płużańska

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A Płużańska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Płużańska. The network helps show where A Płużańska may publish in the future.

Co-authors

The 25 scholars most cited alongside A Płużańska, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with A Płużańska Line = papers co-authored together A Płużańska links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial Onkologie ·Jacek Jassem, Tadeusz Pieńkowski, A Płużańska, S. Jelić, Vera Gorbunova, (unknown), Gotifried Fritzsche, Laura Biganzoli, J. Chen, 周丽君, Stéphane Munier	2009	13
2	First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma Annals of Oncology ·Bohuslav Melichar, P. Koralewski, Alain Ravaud, A Płużańska, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, R. Delva, Emmanuel Sevin, Sylvie Négrier, J McKendrick, Armando Santoro, Pavel Pisa, Bernard Escudier	2008	71
3	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial The Lancet ·Bernard Escudier, A Płużańska, P. Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, Bohuslav Melichar, Emilio Bajetta, В. А. Горбунова, Jacques‐Olivier Bay, I. Bodrogi, Agnieszka Jagiełło-Gruszfeld, N. Moore Hit paper breakdown →	2007	1722
4	D2-04: MERIT: a prospective study of putative relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology ·Eng-Huat Tan, Rodryg Ramlau, A Płużańska, Han‐Pin Kuo, Barbara Klughammer, Mark Kockx, Åsa Melin, Verena Lutz, Laurent Essioux, José Baselga	2007	5
5	Effect of chemotherapy for advanced non-small cell lung cancer on patients’ quality of life Lung Cancer ·Chandra P. Belani, Jose R. Pereira, Joachim von Pawel, A Płużańska, Vera Gorbounova, E. Kaukel, K. Mattson, Rodryg Ramlau, Aleksandra Szczęsna, Panos Fidias, Michael Millward, Frank V. Fossella	2006	48
6	TP53 status determines clinical significance of ERBB2 expression in ovarian cancer British Journal of Cancer ·Jolanta Kupryjańczyk, Radosław Mądry, Joanna Plisiecka-Hałasa, Julia Bar, Ewa Kraszewska, (unknown), Agnieszka Timorek, J Stelmachów, Janusz Emerich, Marcin Jędryka, A Płużańska, I Rzepka-Górska, Krzysztof Urbański, J Zieliński, Janina Markowska	2004	30
7	Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer Annals of Oncology ·Stephen Chan, N. Davidson, Elona Juozaitytė, Frans Erdkamp, A Płużańska, N. Azarnia, Abderaouf BenAbderrahman	2004	114
8	Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer New England Journal of Medicine ·Ian F. Tannock, Ronald de Wit, William R. Berry, J Horti, A Płużańska, Kim N., Stéphane Oudard, Christine Théodore, Nicholas D. James, Ingela Turesson, Mark Rosenthal, Mario A. Eisenberger Hit paper breakdown →	2004	4338
9	An open randomised trial of second-line endocrine therapy in advanced breast cancer European Journal of Cancer ·Carsten Rose, Roser Carbonell Mollà, A Płużańska, Nancy E. Davidson, M. Gershanovich, Robert Thomas, Suzanne M. Johnson, R. Knopp, Helena Gervásio, George Manikhas, Farhat Ben Ayed, Susan Burdette-Radoux, Tom Thomson, D. Hebbeln	2003	145
10	The Role of Intratumoral Therapy With Cisplatin/Epinephrine Injectable Gel in the Management of Advanced Squamous Cell Carcinoma of the Head and Neck Archives of Otolaryngology - Head and Neck Surgery ·Barry L. Wenig, Jochen A. Werner, Dan J. Castro, Kasi S. Sridhar, Harinder S. Garewal, W. Kehrl, A Płużańska, Mike Birmingham, Peter D. Costantino, Glenn Mills, Frank Dunphy, Elaine K. Orenberg, Richard D. Leavitt	2002	30
11	Physical Performance, Toxicity, and Quality of Life as Assessed by the Physician and the Patient Acta Oncologica ·Minna‐Liisa Luoma, Liisa Hakamies‐Blomqvist, Johanna Sjöström, 田中信悟, A Płużańska, Per Malmström, Alida Kouajip-Mabou, Ragnar Hultborn, Madeleine Chávez, Ingvil Mjaaland, Vahur Valvere, Erik Wist, Ranjana Mukhopadhyaya, Johan Ahlgren, Carl Blomqvist	2002	13
12	A phase III placebo-controlled study in advanced head and neck cancer using intratumoural cisplatin/epinephrine gel British Journal of Cancer ·Jochen A. Werner, W. Kehrl, A Płużańska, Mike Birmingham, K.M. Lavery, J. Glaholm, Andreas Dietz, I Kubolli, Steffen Maune, Morgan E. Stewart, Elaine K. Orenberg, Richard D. Leavitt	2002	14
13	Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group European Journal of Cancer ·Liisa Hakamies‐Blomqvist, Minna‐Liisa Luoma, J Sjöström, A Płużańska, Marie Sjödin, Henning T. Mouridsen, Bjørn Østenstad, Ingvil Mjaaland, Sara Mambrilla, Jonas Bergh, Per Malmström, Carl Blomqvist	2000	38
14	A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC) Lung Cancer ·Chandra P. Belani, Frederick Dau, Joachim von Pawel, A Płużańska, Vera Gorbounova, M.J. Millward, Lionel Bosquée, B. Eng, F. Gamza, J. Bérille, Luz Hammershaimb, Frank V. Fossella	2000	43
15	[Pharmacological action of paclitaxel]. PubMed ·Piotr Potemski, A Płużańska	1999	4
16	Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group European Journal of Cancer ·J Sjöström, Carl Blomqvist, Henning T. Mouridsen, A Płużańska, Sara Mambrilla, Nils‐Olof Bengtsson, Bjørn Østenstad, Ingvil Mjaaland, Amirhossein Abdolghaffari, E. Wist, Vahur Valvere, H. Anderson, Jonas Bergh	1999	215
17	Is modified retroperitoneal lymph node dissection (MRLND) still feasible in the treatment of patients with clinical stage I non-seminomatous testicular cancer? International Urology and Nephrology ·Marek Sosnowski, F. Henz, A Płużańska	1994	1
18	Beneficial response of local immunotherapy withPropionibacterium granulosum KP-45 in combined treatment of inflammatory breast carcinoma Journal of Cancer Research and Clinical Oncology ·A Płużańska, 彭二宝, Hanna Wolska, S Szmigielskí, J. Jeljaszewicz, G. Pulverer	1988	1
19	[Blastic transformation of lymphocytes stimulated with phytohemaglutinins as a criterion of evaluation of the clinical state of patients and efficiency of treatment in Hodgkin's disease]. PubMed ·A Płużańska	1969	1
20	[Blastic transformation of lymphocytes in vitro by phytohemagglutinin in lymphogranulomatosis]. PubMed ·A Płużańska	1969	2

About A Płużańska

A Płużańska is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Biotechnology and Otorhinolaryngology, having authored 65 papers that have together received 11.6k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (18 papers), Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (10 papers), Breast Cancer Treatment Studies (9 papers), Lung Cancer Diagnosis and Treatment (7 papers), Renal cell carcinoma treatment (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (8.3k citations), Oncology (6.3k citations), Cancer Research (2.9k citations), Radiology, Nuclear Medicine and Imaging (1.4k citations) and Hematology (610 citations). A Płużańska has collaborated with scholars based in Poland, Germany and United Kingdom. Frequent co-authors include Nicholas D. James, Ronald de Wit, Mario A. Eisenberger, Stéphane Oudard, Ian F. Tannock, Christine Théodore, J Horti, Mark Rosenthal, Kim N. and William R. Berry. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, Lung Cancer and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact